Business context and reporting period
The supplied filing is Nuvilex, Inc.’s Form 10-K for the fiscal year ended April 30, 2013—not a filing identified as Pharmacyte Biotech, Inc. or a report for calendar 2012 Q4. The company reported minimal consumer-product sales and described a strategic shift toward biotechnology and live-cell encapsulation. Its Bio Blue Bird AG (BBB) acquisition was completed after year-end, in July 2013.
Financial results and position
| Metric | FY ended Apr. 30, 2013 | FY ended Apr. 30, 2012 |
|---|---|---|
| Revenue | $12,160 | $66,558 |
| Gross profit | $2,540 | $47,175 |
| Gross margin | 20.9% | 70.9% |
| Operating expenses | $1,686,901 | $1,996,357 |
| Operating loss | $(1,684,361) | $(1,949,182) |
| Net loss | $(1,598,102) | $(1,899,312) |
| Net cash used in operations | $(390,426) | $(259,289) |
Cash at year-end was $199,303, versus $15,723 a year earlier. Total assets were $2,876,931 and total liabilities were $3,798,387; the balance sheet reported negative stockholders’ equity of $1,501,456. Working capital was negative $1,950,234. Current liabilities included $2,341,106 in settlement obligations, $420,000 in loans payable, and $419,583 due to related parties. The filing also identifies a $400,000 licensing-fee obligation under negotiation and a past-due $20,000 note plus interest.
Material changes versus the prior period
- Revenue fell by $54,398, with sales reported solely from Cinnergen. Management said it stopped funding sales activity it considered uneconomic; Cinnergen production and marketing were suspended.
- Net loss narrowed by $301,210. Compensation expense declined by $482,171, while general and administrative expense rose by $201,100. Debt-forgiveness gains and lower interest expense also affected the comparison.
- Operating cash use increased by $131,137. Financing provided $1,220,756, principally from common-stock sales and related-party borrowing; investing used $646,750, primarily for acquisition-related payments.
- Common shares outstanding rose from 416.3 million to 482.1 million during the year. The company issued 39.6 million shares through a private placement that raised $1.136 million, and reported 59.4 million warrants outstanding at a weighted-average exercise price of $0.125.
Outlook, risks, contingencies and unusual items
Management planned to prepare another clinical trial of ifosfamide-converting encapsulated cells for pancreatic and other cancers, with manufacturing support expected from Austrianova Singapore Private Limited (ASPL). The filing reports prior Phase 1/2 studies, but gives no specific trial-start date, financing commitment, revenue forecast, or quantified guidance. Management’s stated plans depend on additional funding and regulatory, manufacturing, purity, toxicology, and clinical work.
The auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. The company reported recurring losses, an accumulated deficit of $41.4 million, minimal revenue, and dependence on further capital. Key risks include clinical-trial delays or adverse events, inability to raise capital, dilution, competition, regulatory approval and market acceptance, and intellectual-property challenges.
After year-end, Nuvilex completed the BBB acquisition for $1.5 million and said BBB held exclusive worldwide licensing rights for live-cell encapsulation in oncology. It also reported that the Cornerstone Bank settlement was satisfied with $702,061 in cash proceeds and that 8,230,637 shares of excess collateral were returned. These subsequent events were not reflected as completed transactions in the April 30, 2013 balance sheet. The filing reports no material pending legal proceedings as of July 29, 2013.
Most important facts for investors to verify
- Confirm the issuer and period: the document is Nuvilex’s FY2013 10-K, despite the request metadata naming Pharmacyte Biotech and 2012 Q4.
- Review the full subsequent-event disclosures and acquisition agreements for BBB, including the $1.5 million purchase terms, licensing rights, and continuing arrangements with SG Austria and ASPL.
- Assess how the company funded operations after year-end and whether financing was sufficient to meet cash needs and advance clinical preparations.
- Reconcile the filing’s statements on internal controls: it says there were no weaknesses, but also says management believed a material weakness remained and that policies had not been fully tested.
- Verify the status and terms of remaining debt, related-party balances, warrants, preferred stock, and post-year-end share issuances; these may affect liquidity, senior claims, and dilution.